Zydus Lifesciences wins USFDA approval for Lubiprostone Capsules to treat constipation

The drug will be manufactured at the group's formulation manufacturing facility in Moraiya, Ahmedabad, India.

Published On 2023-03-24 09:30 GMT   |   Update On 2023-03-24 11:42 GMT
Advertisement

Ahmedabad: Zydus Lifesciences Limited has announced that the company has received final approval for Lubiprostone Capsules, 8 mcg and 24 mcg (USRLD: Amitiza Capsules) from the United States Food and Drug Administration (USFDA).

Lubiprostone capsule is indicated to treat certain types of constipation (chronic idiopathic constipation and irritable bowel syndrome with constipation).

The drug will be manufactured at the group’s formulation manufacturing facility in Moraiya, Ahmedabad (India).

Lubiprostone Capsules, 8 mcg and 24 mcg had annual sales of USD 196.5 mn in the United States (IQVIA MAT, January 2023). The group now has 354 approvals and has so far filed over 440* ANDAs since the commencement of the filing process in FY 2003-04.

Zydus Lifesciences Limited (Formerly known as Cadila Healthcare Limited), an Indian Pharmaceutical company is a fully integrated, global healthcare provider. The company was founded in the year 1952 by Mr. Ramanbhai B. Patel (late), a first-generation entrepreneur and a doyen in the field of Indian Pharmaceuticals.

Read also: Zydus Lifesciences Depression drug Doxepin Hydrochloride bags USFDA okay

Tags:    

Disclaimer: This website is primarily for healthcare professionals. The content here does not replace medical advice and should not be used as medical, diagnostic, endorsement, treatment, or prescription advice. Medical science evolves rapidly, and we strive to keep our information current. If you find any discrepancies, please contact us at corrections@medicaldialogues.in. Read our Correction Policy here. Nothing here should be used as a substitute for medical advice, diagnosis, or treatment. We do not endorse any healthcare advice that contradicts a physician's guidance. Use of this site is subject to our Terms of Use, Privacy Policy, and Advertisement Policy. For more details, read our Full Disclaimer here.

NOTE: Join us in combating medical misinformation. If you encounter a questionable health, medical, or medical education claim, email us at factcheck@medicaldialogues.in for evaluation.

Our comments section is governed by our Comments Policy . By posting comments at Medical Dialogues you automatically agree with our Comments Policy , Terms And Conditions and Privacy Policy .

Similar News